Sale!
CJC-1295 with DAC 5mg 10vials

CJC-1295 with DAC 5mg 10vials

Original price was: $470.00.Current price is: $235.00.

CJC-1295 with DAC is a long-acting GHRH analog featuring a maleimidopropionyl Drug Affinity Complex that covalently binds serum albumin, extending its half-life to 6-8 days. It provides sustained, continuous stimulation of growth hormone and IGF-1 secretion for multi-day neuroendocrine research.

100% delivery

  • Done Satisfaction Guaranteed
  • Done No Hassle Refunds
  • Done Secure Payments
GUARANTEED SAFE CHECKOUT
  • Visa Card
  • MasterCard
Category: Tag:

Description

CJC-1295 with DAC Long-Acting GHRH Analog Research Peptide

Pharmacodynamics

CJC-1295 with DAC actively targets the somatotrophs of the anterior pituitary gland. The peptide covalently binds to endogenous serum albumin. This specific bioconjugation interaction aggressively shields the peptide from dipeptidyl peptidase-4 (DPP-4) enzymatic cleavage. The resulting stable complex continuously stimulates the GHRH receptor. Compared to CJC-1295 without DAC??which induces a sharp 30-minute physiological pulse??the addition of the reactive maleimidopropionyl group (DAC) dictates a continuous, steady-state elevation of growth hormone and IGF-1. Quantitative research confirms an exceptionally prolonged biological half-life spanning approximately 5.8 to 8.1 days in systemic circulation. This allows researchers to observe sustained, multi-day neuroendocrine cascades.

Specification Sheet

  • Sequence Modification: Tetrasubstituted GRF 1-29 plus C-terminal Maleimidopropionyl
  • Molecular Formula: C163H267N47O46
  • Molecular Weight: ~3647.3 g/mol
  • Purity: >99% (HPLC validated)
  • Appearance: Sterile filtered white lyophilized powder

Known Effects

  • Users frequently report sustained improvements in deep sleep architecture and nocturnal recovery.
  • Study data demonstrates a continuous, steady elevation in baseline systemic IGF-1 levels.
  • Cross-study analysis suggests prolonged metabolic support for lipolysis and shifts in body composition.
  • Researchers note increased localized tissue repair and collagen synthesis over extended protocol durations.

Overview

CJC-1295 with DAC (Drug Affinity Complex) is an advanced, synthetically modified peptide engineered to stimulate endogenous growth hormone production. By integrating a targeted bioconjugation technology, researchers have fundamentally extended the compound’s pharmacokinetic activity window, allowing for sustained systemic evaluation rather than transient, episodic pulsing.
In Brief:
CJC-1295 with DAC provides an incredibly stable, long-acting research vector for investigating continuous, steady-state elevations of endogenous growth hormone and IGF-1.

Frequently Asked Questions

[Q] How does ‘with DAC’ differ from ‘without DAC’?

The Drug Affinity Complex allows the peptide to bind to blood albumin, extending its half-life from 30 minutes to over a week.

[Q] How frequently should this peptide be administered?

Because of its sustained release profile, community consensus strongly advises administering this compound only once per week.

[Q] What is the typical user dosage per week?

Experienced researchers typically report utilizing a standard dosage of 1mg to 2mg per weekly subcutaneous injection.

[Q] Does this compound cause water retention?

Yes, because it constantly elevates systemic growth hormone levels, users often report more significant fluid retention than with short-acting pulses.

[Q] How should the mixed vial be stored?

Once reconstituted with Bacteriostatic Bac.water, the multi-dose vial must remain refrigerated at 2??C to 8??C to prevent degradation.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.

Reviews

There are no reviews yet.

Be the first to review “CJC-1295 with DAC 5mg 10vials”

Related products